Guest guest Posted March 11, 2011 Report Share Posted March 11, 2011 Regarding the debate over FDA approval of LDN;Dr. Skip's example was 4-Aminopyridine (4-AP), a drug whose patent expired some time ago, still being legally prescribed and compounded for ms patients' use.Ampyra is now a commercially available, FDA approved drug that is a slow release version of 4-AP. Ampyra is considerably more expensive than 4-AP but should be covered by health insurance because it is labeled for use by ms patients.I still purchase the compounded 4-AP because I don't have health insurance and am unsure of the efficacy of the slow release version. I know the results I get with the 4-AP, and can still afford it.So, why wouldn't LDN still be available as an off-label prescription like 4-AP is? Just because a pharmaceutical company patents a version of it with a new name, why would the compounded off-label version be discarded?Just wondering...Carolyn Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.